BIOPSYCHOSOCIAL BURDEN OF IRRITABLE BOWEL SYNDROME: A NARRATIVE REVIEW OF QUALITY OF LIFE, MENTAL HEALTH AND DIGITAL HEALTH PERSPECTIVES
Authors:
- Szczepan PółchłopekSPSzczepan Półchłopek
- Kacper SzpanelewskiKSKacper Szpanelewski
- Radosław KołodziejRKRadosław Kołodziej
- Anna KołodziejAKAnna Kołodziej
- Szymon LulekSLSzymon Lulek
- Jakub KlechaJKJakub Klecha
- Emilia KucabEKEmilia Kucab
- Katarzyna DzikiKDKatarzyna Dziki
- Izabela KulaIKIzabela Kula
- Joanna CiemięGaJCJoanna CiemięGa
- Wiktor AdamiecWAWiktor Adamiec
- Damian DanilczukDDDamian Danilczuk
Open Access
- 30 June 2026
- journal article
- review article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Abstract
Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction characterized by recurrent abdominal pain associated with altered bowel habits in the absence of structural abnormalities that could fully explain the reported symptoms. Despite the lack of organic lesions typical of structural gastrointestinal diseases, IBS remains a significant diagnostic and therapeutic challenge because of its heterogeneous clinical presentation, multifactorial pathogenesis, and substantial impact on patients’ quality of life. The aim of this review was to summarize current evidence regarding epidemiology, pathogenesis, clinical presentation, diagnosis, treatment, and quality-of-life burden associated with IBS. Particular attention was paid to the variability in prevalence estimates depending on diagnostic criteria and study methodology, as well as to the role of the gut-brain axis, gut microbiota, visceral hypersensitivity, immune activation, and psychosocial factors in the development and persistence of symptoms. The review also highlights the importance of a positive diagnostic strategy based on Rome IV criteria, identification of alarm features, and selective use of additional tests. Current therapeutic approaches require individualized and integrated management that combines patient education, dietary interventions, psychological therapies, and symptom-directed pharmacological treatment. IBS does not increase mortality; however, it markedly impairs social, occupational, and emotional functioning. A multidimensional, biopsychosocial approach therefore appears essential for improving both symptom control and overall patient well-being.Keywords
This publication has 20 references indexed in Scilit:
- Pathophysiological Mechanisms and Nonpharmacological Interventions in Irritable Bowel Syndrome: Current Insights and Future DirectionsJournal of Nutrition and Metabolism, 2026
- Quality of life, functional impairment and healthcare experiences of patients with irritable bowel syndrome in Norway: an online surveyBMC Gastroenterology, 2025
- An evidence-based update on the diagnosis and management of irritable bowel syndromeExpert Review of Gastroenterology & Hepatology, 2025
- Work-related problems and the psychosocial characteristics of individuals with irritable bowel syndrome: an updated literature reviewBioPsychoSocial Medicine, 2024
- Psychological factors may affect the quality of life in irritable bowel syndrome patients more than the gut itself? A multicenter cross‐sectional studyJGH Open, 2024
- Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary managementNature Reviews Gastroenterology & Hepatology, 2023
- Prevalence, epidemiology and associated healthcare burden of Rome IV irritable bowel syndrome and functional dyspepsia in the adult population of GibraltarBMJ Open Gastroenterology, 2022
- Impact of Rome IV irritable bowel syndrome on work and activities of daily livingAlimentary Pharmacology & Therapeutics, 2022
- British Society of Gastroenterology guidelines on the management of irritable bowel syndromeGut, 2021
- Stigma and irritable bowel syndrome: a taboo subject?The Lancet Gastroenterology & Hepatology, 2020